Name | BI-135585 |
---|---|
Synonyms |
(6S)-6-(2-Hydroxy-2-methylpropyl)-3-{(1S)-1-[4-(1-methyl-2-oxo-1,2-dihydro-4-pyridinyl)phenyl]ethyl}-6-phenyl-1,3-oxazinan-2-one
BI-135585 DA4HT8614K 2H-1,3-Oxazin-2-one, 3-[(1S)-1-[4-(1,2-dihydro-1-methyl-2-oxo-4-pyridinyl)phenyl]ethyl]tetrahydro-6-(2-hydroxy-2-methylpropyl)-6-phenyl-, (6S)- |
Description | BI-135585 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor with an IC50 of 13 nM. BI-135585 exhibits >1000-fold selectivity over other hydroxysteroid dehydrogenases. BI-135585 can be used for type 2 diabetes research[1][2]. |
---|---|
Related Catalog | |
Target |
IC50: 13 nM (11β-HSD1)[1] |
In Vitro | BI-135585 binds in the substrate binding pocket of the active site of 11β-HSD1. Cellular activity of BI-135585 is examined by determining inhibition of 11β-HSD1 activity in human preadipocytes, the average IC50 is 1 nM[1]. In human adipose tissue ex vivo, BI-135585 inhibits the conversion of cortisone to cortisol with an average IC50 of 11 nM[1]. Abdominal subcutaneous and perirenal adipose tissue was harvested from one, male cynomolgus monkey. BI-135585 (20 hours) reduces enzyme activity in a dose-dependent manner with an IC50 of ~10 nM in perirenal adipose tissue and an IC50 of ~100 nM in abdominal subcutaneous adipose tissue[1]. |
In Vivo | BI-135585 (compound 11j; 1-3 mg/kg; po) inhibits 67% and 90% of enzyme activity respectively in perirenal adipose tissue in cynomolgus monkey[2]. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 703.6±60.0 °C at 760 mmHg |
Molecular Formula | C28H32N2O4 |
Molecular Weight | 460.565 |
Flash Point | 379.3±32.9 °C |
Exact Mass | 460.236206 |
LogP | 3.69 |
Vapour Pressure | 0.0±2.3 mmHg at 25°C |
Index of Refraction | 1.596 |